{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:13:03Z","timestamp":1788970383367,"version":"build-2803163510"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify the factors associated with this symptom in patients with non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective multicenter observational study evaluated 170 patients with NSCLC who received DTX between April 2014 and December 2024. The primary endpoint was factors associated with grade\u00a0\u2265\u00a02 DTX-induced peripheral edema during up to seven cycles. Additionally, we evaluated the factors for all-grade symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidences of grade\u00a0\u2265\u00a02 and all-grade DTX-induced peripheral edema were 13.5% and 30.0%. The median cumulative DTX dose at symptom onset was 144 (interquartile range, 60\u2013254) mg\/m2 for grade\u00a0\u2265\u00a02 DTX-induced peripheral edema and 120 (60\u2013210) mg\/m2 for all-grade symptoms. The Fine-Gray sub-distribution hazard models revealed that the co-administration of ramucirumab (RAM) was significantly associated with the incidence of DTX-induced peripheral edema (grade\u00a0\u2265\u00a02: sub-distribution hazard ratio [SDHR], 3.51; 95% confidence interval [CI], 1.34\u20139.24; P\u00a0=\u00a00.011) (all-grade: SDHR, 2.17; 95% CI, 1.20\u20133.92; P\u00a0=\u00a00.011). The Gray\u2019s test demonstrated that the cumulative incidence of DTX-induced peripheral edema was significantly higher in the DTX\u00a0+\u00a0RAM group than in the DTX monotherapy group (P\u00a0=\u00a00.003 and\u00a0&amp;lt;\u00a00.001 for grade\u00a0\u2265\u00a02 and all-grade symptoms, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We revealed that co-administration of RAM is a risk factor for DTX-induced peripheral edema in patients with NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag091","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:45:44Z","timestamp":1779450344000},"page":"1088-1096","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study"],"prefix":"10.1093","volume":"56","author":[{"given":"Shinsuke","family":"Yamashita","sequence":"first","affiliation":[{"name":"Graduate School of Life Science, Hokkaido University , Kita 10 Nishi 8, Kita-ku, Sapporo, Hokkaido 060-0810 ,","place":["Japan"]},{"name":"Department of Pharmacy, Hokkaido University Hospital , Kita 14 Nishi 5, Kita-ku, Sapporo, Hokkaido 060-8648 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science , Maeda 7-Jo, 15-Chome, Teine-ku, Sapporo, Hokkaido 006-8585 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, KKR Sapporo Medical Center , 3-40 Hiragishi 1-jo 6-chome, Toyohira-ku, Sapporo, Hokkaido 062-0931 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hirate","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Teine Keijinkai Hospital , 1-40 Maeda 1-jo 12-chome, Teine-ku, Sapporo, Hokkaido 006-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Wakai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Teine Keijinkai Hospital , 1-40 Maeda 1-jo 12-chome, Teine-ku, Sapporo, Hokkaido 006-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuki","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, KKR Sapporo Medical Center , 3-40 Hiragishi 1-jo 6-chome, Toyohira-ku, Sapporo, Hokkaido 062-0931 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honoka","family":"Hirasawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, KKR Sapporo Medical Center , 3-40 Hiragishi 1-jo 6-chome, Toyohira-ku, Sapporo, Hokkaido 062-0931 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University , Kita 12 Nishi 6, Kita-ku, Sapporo, Hokkaido 060-0812 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University , Kita 12 Nishi 6, Kita-ku, Sapporo, Hokkaido 060-0812 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-613X","authenticated-orcid":false,"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University , Kita 12 Nishi 6, Kita-ku, Sapporo, Hokkaido 060-0812 ,","place":["Japan"]},{"name":"Division of Drug Informatics, Keio University Faculty of Pharmacy , 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nashimoto","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University , Kita 12 Nishi 6, Kita-ku, Sapporo, Hokkaido 060-0812 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University , Kita14, Nishi5, Kita-Ku, Sapporo, Hokkaido 060-8648 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takagi","sequence":"additional","affiliation":[{"name":"Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital , Kita 14, Nishi 5,Kita-ku, Sapporo, Hokkaido 060-8648 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital , Kita 14 Nishi 5, Kita-ku, Sapporo, Hokkaido 060-8648 ,","place":["Japan"]},{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University , Kita 12 Nishi 6, Kita-ku, Sapporo, Hokkaido 060-0812 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital , Kita 14 Nishi 5, Kita-ku, Sapporo, Hokkaido 060-8648 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"key":"2026090910441763400_ref1","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"2026090910441763400_ref2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"2026090910441763400_ref3","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"2026090910441763400_ref4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1046\/j.1365-2125.1997.00613.x","article-title":"The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication","volume":"43","author":"B\u00e9har","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"2026090910441763400_ref5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000336480","article-title":"Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: the National Surgical Adjuvant Study of breast cancer 02","volume":"82","author":"Ohsumi","year":"2012","journal-title":"Oncology"},{"key":"2026090910441763400_ref6","doi-asserted-by":"publisher","first-page":"9247","DOI":"10.1038\/s41598-023-36264-4","article-title":"High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment","volume":"13","author":"Saito","year":"2023","journal-title":"Sci Rep"},{"key":"2026090910441763400_ref7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026090910441763400_ref8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"2026090910441763400_ref9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2016.07.019","article-title":"A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy","volume":"99","author":"Yoh","year":"2016","journal-title":"Lung Cancer"},{"key":"2026090910441763400_ref10","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","article-title":"Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026090910441763400_ref11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","article-title":"The Japanese lung cancer society guideline for non-small cell lung cancer, stage IV","volume":"24","author":"Akamatsu","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2026090910441763400_ref12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12282-023-01505-x","article-title":"The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2022 edition","volume":"30","author":"Terada","year":"2023","journal-title":"Breast Cancer"},{"key":"2026090910441763400_ref13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/annonc\/mdi018","article-title":"Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)","volume":"16","author":"Gervais","year":"2005","journal-title":"Ann Oncol"},{"key":"2026090910441763400_ref14","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1111\/bcp.14614","article-title":"Dose individualisation in oncology using chemotherapy-induced neutropenia: example of docetaxel in non-small cell lung cancer patients","volume":"87","author":"Lombard","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026090910441763400_ref15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","article-title":"2023 Japan Society of Clinical Oncology clinical practice guidelines update for antiemesis","volume":"29","author":"Iihara","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2026090910441763400_ref16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/j.pain.0000000000001577","article-title":"Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study","volume":"160","author":"Hincker","year":"2019","journal-title":"Pain"},{"key":"2026090910441763400_ref17","doi-asserted-by":"publisher","first-page":"1950411","DOI":"10.1080\/2162402X.2021.1950411","article-title":"Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study","volume":"10","author":"Morimoto","year":"2021","journal-title":"Oncoimmunology"},{"key":"2026090910441763400_ref18","doi-asserted-by":"publisher","first-page":"e0260742","DOI":"10.1371\/journal.pone.0260742","article-title":"Peripheral edema: a common and persistent health problem for older Americans","volume":"16","author":"Besharat","year":"2021","journal-title":"PloS One"},{"key":"2026090910441763400_ref19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3121\/cmr.2009.819","article-title":"Reliability and feasibility of methods to quantitatively assess peripheral edema","volume":"7","author":"Brodovicz","year":"2009","journal-title":"Clin Med Res"},{"key":"2026090910441763400_ref20","doi-asserted-by":"publisher","first-page":"100154","DOI":"10.1016\/j.xjidi.2022.100154","article-title":"Enhancing techniques for determining inflammatory edema formation and neutrophil accumulation in murine skin","volume":"3","author":"Zarban","year":"2023","journal-title":"JID Innov"},{"key":"2026090910441763400_ref21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0002-9343(02)01322-0","article-title":"Peripheral edema","volume":"113","author":"Cho","year":"2002","journal-title":"Am J Med"},{"key":"2026090910441763400_ref22","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1007\/s10620-023-07984-4","article-title":"Predictors of liver dysfunction after transhepatic arterial chemo-embolization in hepatocellular carcinoma patients","volume":"68","author":"Cheng","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2026090910441763400_ref23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2026090910441763400_ref24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026090910441763400_ref25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s12282-020-01088-x","article-title":"Risk factors for breast cancer-related lymphedema: correlation with docetaxel administration","volume":"27","author":"Aoishi","year":"2020","journal-title":"Breast Cancer"},{"key":"2026090910441763400_ref26","doi-asserted-by":"publisher","first-page":"1026043","DOI":"10.3389\/fonc.2022.1026043","article-title":"Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"key":"2026090910441763400_ref27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12282-011-0297-y","article-title":"A lower dose of docetaxel at 60 mg\/m2 could be continued longer for controlling peripheral edema in patients with metastatic breast cancer","volume":"19","author":"Hosonaga","year":"2012","journal-title":"Breast Cancer"},{"key":"2026090910441763400_ref28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/1097-0142(19950701)76:1&lt;110::aid-cncr2820760117&gt;3.0.co;2-9","article-title":"Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities: a report of three cases","volume":"76","author":"Battafarano","year":"1995","journal-title":"Cancer"},{"key":"2026090910441763400_ref29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12328-020-01265-7","article-title":"Docetaxel-induced fluid retention during adjuvant chemotherapy with S-1 plus docetaxel","volume":"14","author":"Tsuji","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"2026090910441763400_ref30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.13048\/jkm.14049","article-title":"A case report of improvement of docetaxel-induced fluid retention in a patient with advanced gastric cancer using herbal decoction, modified Bangkihwangki-tang","volume":"35","author":"Choi","year":"2014","journal-title":"J Korean Med"},{"key":"2026090910441763400_ref31","doi-asserted-by":"publisher","first-page":"H963","DOI":"10.1152\/ajpheart.01052.2003","article-title":"Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure","volume":"287","author":"Br\u00f8nstad","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026090910441763400_ref32","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1158\/0008-5472.CAN-05-1843","article-title":"Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2","volume":"66","author":"Roberts","year":"2006","journal-title":"Cancer Res"},{"key":"2026090910441763400_ref33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1096\/fj.06-6656com","article-title":"Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis","volume":"21","author":"Goldman","year":"2007","journal-title":"FASEB J"},{"key":"2026090910441763400_ref34","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.cardfail.2023.04.006","article-title":"Relationship of vascular endothelial growth factor C, a lymphangiogenesis modulator, with edema formation, congestion and outcomes in acute heart failure","volume":"29","author":"Iwanek","year":"2023","journal-title":"J Card Fail"},{"key":"2026090910441763400_ref35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40780-024-00372-8","article-title":"Effect of blood pressure control on the risk of proteinuria during bevacizumab treatment in patients with colorectal cancer: a single-center retrospective cohort study","volume":"10","author":"Nihei","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"2026090910441763400_ref36","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1084\/jem.20021244","article-title":"Vascular permeability factor\/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis","volume":"196","author":"Nagy","year":"2002","journal-title":"J Exp Med"},{"key":"2026090910441763400_ref37","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00280-018-3580-1","article-title":"Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab","volume":"81","author":"Nihei","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026090910441763400_ref38","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090910441763400_ref39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000541621","article-title":"Higher risk of proteinuria with atezolizumab plus bevacizumab than lenvatinib in first-line systemic treatment for hepatocellular carcinoma","volume":"14","author":"Yang","year":"2025","journal-title":"Liver Cancer"},{"key":"2026090910441763400_ref40","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2147\/OTT.S61132","article-title":"Ramucirumab: preclinical research and clinical development","volume":"7","author":"Aprile","year":"2014","journal-title":"Onco Targets Ther"},{"key":"2026090910441763400_ref41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2026090910441763400_ref42","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3390\/cancers15061691","article-title":"Phase 1 study to evaluate the safety of reducing the prophylactic dose of dexamethasone around docetaxel infusion in patients with prostate and breast cancer","volume":"15","author":"Lugtenberg","year":"2023","journal-title":"Cancers"},{"key":"2026090910441763400_ref43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/10781552241232692","article-title":"Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: a safety net hospital experience","volume":"31","author":"Hager","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"2026090910441763400_ref44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/9\/1088\/70099761\/hyag091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/9\/1088\/70099761\/hyag091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:29:38Z","timestamp":1788967778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/9\/1088\/8742069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,7,26]]},"published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag091","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,26]]}}}